Probiotics in the Management of Esophageal Cancer: A Comprehensive Review of Therapeutic Potential and Supportive Clinical Effects
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Esophageal cancer (EC) remains a highly aggressive malignancy with poor prognosis, largely due to the toxicity of multimodal treatments and postoperative complications. Probiotics have emerged as potential adjuncts in cancer therapy, offering both direct anticancer properties and supportive effects that enhance treatment tolerance and patient outcomes. Methods: This review identified relevant preclinical and clinical studies on probiotics in esophageal cancer therapies through comprehensive searches of Google Scholar, Medline/PubMed, Scopus, Web of Science, and clinicaltrials.gov following PRISMA 2020 guidelines. Results: Preclinical evidence has demonstrated that Lactobacillus strains, particularly L. casei, L. rhamnosus, and L. plantarum, and their metabolites (e.g., ferrichrome, bacteriocins), exert antitumor effects through the induction of apoptosis, inhibition of the Wnt/β-catenin pathway, and cell-cycle arrest, with efficacy comparable to that of 5-fluorouracil in some models and favorable toxicological profiles. Clinically, synbiotic supplementation combining Bifidobacterium breve, Lactobacillus casei/paracasei, and galacto-oligosaccharides consistently reduced chemotherapy-induced diarrhea (OR=0.39, 95%CI [0.22–0.71];p
Fields of Study & Subjects
Probiotics and Fermented Foods
Bacterial Cancer Therapy
Esophageal Cancer Research and Treatment
Publication details
- Journal / source
- Archives of Pharmaceutical Sciences Ain Shams University
- Volume
- 0
- Issue
- 0
- Publication date
- 25 March 2026
- Language
- EN